Early results back M-Biotech's implantable glucose monitor
This article was originally published in Clinica
M-Biotech says that proof-of-concept data look promising for its new implantable glucose biosensor. The device, which the firm claims is "unlike other implantable systems", targets a market worth over $1bm in the US alone, says the company.
You may also be interested in...
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.